StockData
Vaxart, Inc. logo

Vaxart, Inc. (VXRT) stock

VXRTOTCBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 11/30
$0.48+0.02 (+5.04%)

Close on Oct 19, 2026Market cap $115.15MP/E 3.2Yield –

Vaxart shares outstanding

Diluted shares outstanding: the weighted share count used for earnings per share, adjusted for stock splits.

Vaxart's shares outstanding was 242M at Jun 30, 2026. For fiscal 2025 it was 230M, up 14.0% from the year before. Over ten years it grew 22.1% a year on average. The highest annual figure on record is 230M in fiscal 2025.

Annual shares outstanding

PeriodPeriod endValueChange
FY2025Dec 31, 2025230M+14.0%
FY2024Dec 31, 2024202M+39.6%
FY2023Dec 31, 2023145M+13.4%
FY2022Dec 31, 2022128M+5.1%
FY2021Dec 31, 2021121M+37.6%
FY2020Dec 31, 202088M+309.4%
FY2019Dec 31, 201922M+241.5%
FY2018Dec 31, 20186M-83.7%
FY2016Jun 30, 201639M+9.3%
FY2015Jun 30, 201535M+12.8%
FY2014Jun 30, 201431M+11.1%
FY2013Jun 30, 201328M+24.2%
FY2012Jun 30, 201223M-55.1%
FY2009Dec 26, 200951M–

Quarterly shares outstanding

Change is against the same quarter a year earlier.

Periods
PeriodPeriod endValueChange
Q2 FY2026CQ2 2026Jun 30, 2026242M+6.0%
Q1 FY2026CQ1 2026Mar 31, 2026242M+6.3%
Q4 FY2025CQ4 2025Dec 31, 2025236M+3.6%
Q3 FY2025CQ3 2025Sep 30, 2025229M+0.6%
Q2 FY2025CQ2 2025Jun 30, 2025228M+23.6%
Q1 FY2025CQ1 2025Mar 31, 2025228M+35.0%
Q4 FY2024CQ4 2024Dec 31, 2024228M+60.4%
Q3 FY2024CQ3 2024Sep 30, 2024227M+49.6%
Q2 FY2024CQ2 2024Jun 30, 2024185M+32.3%
Q1 FY2024CQ1 2024Mar 31, 2024169M+24.8%
Q4 FY2023CQ4 2023Dec 31, 2023142M+7.8%
Q3 FY2023CQ3 2023Sep 30, 2023152M+19.8%
Q2 FY2023CQ2 2023Jun 30, 2023140M+10.4%
Q1 FY2023CQ1 2023Mar 31, 2023135M+7.5%
Q4 FY2022CQ4 2022Dec 31, 2022132M+4.9%
Q3 FY2022CQ3 2022Sep 30, 2022127M+2.3%
Q2 FY2022CQ2 2022Jun 30, 2022126M+4.6%
Q1 FY2022CQ1 2022Mar 31, 2022126M+9.0%
Q4 FY2021CQ4 2021Dec 31, 2021125M+14.3%
Q3 FY2021CQ3 2021Sep 30, 2021124M+15.1%
Q2 FY2021CQ2 2021Jun 30, 2021121M+61.9%
Q1 FY2021CQ1 2021Mar 31, 2021115M+90.2%
Q4 FY2020CQ4 2020Dec 31, 2020110M+575.9%
Q3 FY2020CQ3 2020Sep 30, 2020108M+637.9%
Q2 FY2020CQ2 2020Jun 30, 202075M+922.8%
Q1 FY2020CQ1 2020Mar 31, 202061M+748.6%
Q3 FY2019CQ3 2019Sep 30, 201916M+127.5%
Q2 FY2019CQ2 2019Jun 30, 201915M+104.4%
Q1 FY2019CQ1 2019Mar 31, 20197M+37.8%
Q4 FY2018CQ4 2018Dec 31, 20187M-81.5%
Q3 FY2018CQ3 2018Sep 30, 20187M-81.5%
Q2 FY2018CQ2 2018Jun 30, 20187M-81.5%
Q1 FY2018CQ1 2018Mar 31, 20185M-86.3%
Q4 FY2016CQ2 2016Jun 30, 201639M+7.1%
Q3 FY2016CQ1 2016Mar 31, 201639M+10.0%
Q2 FY2016CQ4 2015Dec 31, 201539M–
Q1 FY2016CQ3 2015Sep 30, 201539M–
Q4 FY2015CQ2 2015Jun 30, 201536M–
Q3 FY2015CQ1 2015Mar 31, 201535M–

More Vaxart figures

See a number that looks wrong?